UCSF team discovers new way to predict breast cancer survival and enhance effectiveness of treatment

Key points
- A team of researchers at the University of California, San Francisco has discovered a new way to predict breast cancer survival based on an "immune profile" – the relative levels of three types of immune cells within a tumor.
- Moreover, the UCSF team showed that they could use drugs to alter this immune profile in mice.
- According to UCSF Department of Pathology Professor Lisa Coussens, PhD, who led the research, a clinical trial for women with advanced breast cancer based on this discovery should begin enrolling patients at the UCSF Helen Diller Family Comprehensive Cancer Center and two collaborating institutions later this year.
- "If our work translates into the clinic," said Coussens, "it may improve the effectiveness of chemotherapy in the treatment of certain cancers."
A team of researchers at the University of California, San Francisco has discovered a new way to predict breast cancer survival based on an "immune profile" – the relative levels of three types of immune cells within a tumor. Knowing a patient's profile may one day help guide treatment.
Moreover, the UCSF team showed that they could use drugs to alter this immune profile in mice. Giving these drugs to mice, in combination with chemotherapy, significantly slowed tumor growth, blocked metastasis and helped mice live longer, suggesting that the approach may work in people.
According to UCSF Department of Pathology Professor Lisa Coussens, PhD, who led the research, a clinical trial for women with advanced breast cancer based on this discovery should begin enrolling patients at the UCSF Helen Diller Family Comprehensive Cancer Center and two collaborating institutions later this year.
"If our work translates into the clinic," said Coussens, "it may improve the effectiveness of chemotherapy in the treatment of certain cancers."
A research article describing this discovery appears in the inaugural issue of the journal Cancer Discovery today. Coussens also is presenting the results at the American Association for Cancer Research meeting in Orlando, FL this week.
WHY ISN'T THE BODY IMMUNE TO CANCER?
Breast cancer continues to be a major health problem in the United States, and the National Cancer Institute estimates more than 200,000 Americans are diagnosed with the disease every year. It is the second leading cause of cancer death among American women, claiming more than 40,000 lives in 2009 alone.
Basic cancer research at UCSF, and elsewhere across the country, seeks to address this problem by asking fundamental questions about the disease. A few years ago, Coussens and her colleagues were doing just that, wondering: Why isn't the body more immune to cancer?
Scientists have known for years that the immune system is closely linked to cancer because it naturally keeps cancer in check – or at least it's supposed to. The body is filled with immune cells that seek out and destroy tumors, but those cells often prove ineffective at controlling cancer completely. Moreover, certain types of cancer can actually co-opt immune cells and use them to help tumors grow.
Normally the immune system protects the body by unleashing on tumors an immune cell called a killer T cell. This cell is effective, but dangerous. It can shrink tumors, but it also can damage healthy tissue. So the immune system uses another type of immune cell, called a macrophage, to control killer T cells, calling them where needed and shutting them down to keep them from damaging healthy tissue.
Coussens and her colleagues found that some cancers subvert this process by using macrophages to suppress the killer T cells and keep them away from tumors.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsDNA marker predicts platinum drug response in breast, ovarian cancer
Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers…
23 March 2012
NewsNew breast cancer gene may help predict risk
Screening for mutations in a gene known as CHEK2 may help determine a woman's odds of breast cancer if the disease runs in her family, Polish scientists suggested Monday. A woman harboring a CHEK2 mutation, for…
30 August 2011
NewsCSHL team identifies enzyme that is an important regulator of aggressive breast cancer development
Researchers at Cold Spring Harbor Laboratory (CSHL) have identified an enzyme that appears to be a significant regulator of breast cancer development. Called PTPN23, the enzyme is a member of a family called protein…



